MARKET

LRMR

LRMR

Larimar Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

16.00
-1.26
-7.30%
Closed 16:00 01/27 EST
OPEN
16.40
PREV CLOSE
17.26
HIGH
17.11
LOW
16.00
VOLUME
23.45K
TURNOVER
--
52 WEEK HIGH
25.87
52 WEEK LOW
7.43
MARKET CAP
245.70M
P/E (TTM)
-3.6952
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Is LRMR A Good Stock To Buy Now?
Insider Monkey · 12/17/2020 00:23
Larimar, Avadel, Applied Therapeutics will added to Nasdaq Biotechnology Index
Larimar Therapeutics ([[LRMR]] -3.4%), Avadel Pharmaceuticals ([[AVDL]] +1.7%) and Applied Therapeutics ([[APLT]] +2.5%) have been selected to be included in the NASDAQ Biotechnology Index.The addition to the index will become
Seekingalpha · 12/15/2020 16:30
Larimar Therapeutics Added to NASDAQ Biotechnology Index
Larimar Therapeutics, Inc. ("Larimar") (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq: NBI)...
GlobeNewswire · 12/15/2020 13:00
Larimar Therapeutics Added to NASDAQ Biotechnology Index
BALA CYNWYD, Pa., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that it has been selected for addi...
GlobeNewswire · 12/15/2020 13:00
The Daily Biotech Pulse: Roche & Moderna Strike COVID Testing Partnership, Rocket Pharma's Gene Therapy Readout, Breast Cancer Presentations
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 8)
Benzinga · 12/09/2020 12:23
Larimar completes dosing in Friedreich’s Ataxia, provides program update
Larimar Therapeutics (LRMR) has completed dosing of its Phase 1 single ascending dose ((SAD)) clinical trial (n=28) evaluating CTI-1601 as a treatment for Friedreich’s ataxia ((FA)) and provides additional updates
Seekingalpha · 12/08/2020 13:25
Larimar Therapeutics Announces Completion of Dosing of the Single Ascending Dose Clinical Trial in Friedreichs Ataxia Patients and Provides Program Update
\- Preliminary data suggest that single subcutaneous injections of CTI-1601 were well tolerated at doses up to 100 mg \- Company remains on track to report topline data from placebo-controlled single and multiple ascending dose clinical trials in Q2 2021B...
GlobeNewswire · 12/08/2020 12:30
The Daily Biotech Pulse: Lilly Secures Additional Orders For COVID-19 Antibody Treatment, Decision Day For BioCryst, Kinnate Biopharma To Make Wall Street Debut
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 2)
Benzinga · 12/03/2020 12:46
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of LRMR. Analyze the recent business situations of Larimar Therapeutics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average LRMR stock price target is 0.7800 with a high estimate of 0.7800 and a low estimate of 0.7800.
EPS
Institutional Holdings
Institutions: 85
Institutional Holdings: 13.90M
% Owned: 90.54%
Shares Outstanding: 15.36M
TypeInstitutionsShares
Increased
11
613.51K
New
11
234.70K
Decreased
6
176.45K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.27%
Pharmaceuticals & Medical Research
-3.25%
Key Executives
Chairman/Director
Joseph Truitt
President/Chief Executive Officer/Director
Carole Ben-Maimon
Chief Financial Officer
Michael Celano
Other
Brian McVeigh
Other
Priya Singhal
Director
Thomas Hamilton
Director
Jonathan Leff
Director
Geoffrey McDonough
Independent Director
Thomas Daniel
Independent Director
John LaMattina
Independent Director
Frank Thomas
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
About LRMR
Larimar Therapeutics Inc., formerly Zafgen, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for complex rare diseases using its cell penetrating peptide technology platform. The Company’s protein replacement therapy platform provides disease-modifying therapies that intends to deliver missing proteins inside the machinery of cells to treat devastating rare diseases that have no treatments available. The Company’s lead product candidate, CTI-1601, is a recombinant fusion protein intended to deliver human frataxin (FXN) into the mitochondria of patients with Friedreich’s ataxia (FA). CTI-1601 is in Phase I clinical program. The Company intends to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.

Webull offers kinds of Larimar Therapeutics Inc stock information, including NASDAQ:LRMR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LRMR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LRMR stock methods without spending real money on the virtual paper trading platform.